论文部分内容阅读
目的研究新辅助化疗周期数对ⅢA期乳腺癌无进展生存(PFS)及5 a总生存(OS)的影响,评价其安全性及可行性。方法 61例ⅢA期乳腺癌患者随机分为新辅助化疗4周期组37例和2周期组24例,患者确诊后分别接受4个周期和2周期的全身化疗,然后手术、术后辅助化疗。比较2组无进展生存,总生存,化疗的毒性反应。结果新辅助化疗4周期和2周期组平均无进展生存分别为52.71个月、32.71个月,两组比较P<0.05,差异有统计学意义(P<0.05);5 a总生存,4周期组94.6%,2周期组79.1%,差异有统计学意义(P<0.05)。结论新辅助化疗4周期较2周期可明显提高ⅢA期乳腺癌患者的无进展生存及5 a总生存,而不良反应相似。
Objective To study the effect of neoadjuvant chemotherapy cycles on the progression-free survival (PFS) and 5-year overall survival (OS) of stage ⅢA breast cancer and to evaluate its safety and feasibility. Methods Sixty-one patients with stage ⅢA breast cancer were randomly divided into two groups: 37 in the 4-week neoadjuvant chemotherapy group and 24 in the 2-week period group. Patients were treated with 4 cycles and 2 cycles of systemic chemotherapy respectively, followed by surgery and postoperative adjuvant chemotherapy. Two groups of progression-free survival, total survival, chemotherapy toxicity. Results The average progression-free survival rates in the 4 and 2 cycles of neoadjuvant chemotherapy were 52.71 months and 32.71 months respectively. There was significant difference between the two groups (P <0.05) 94.6%, 79.1% in 2 cycles group, the difference was statistically significant (P <0.05). Conclusions Neoadjuvant chemotherapy 4 cycles can significantly improve the progression-free survival and 5-year overall survival of patients with stage ⅢA breast cancer compared with 2 cycles, and the adverse reactions are similar.